Total Voting Rights Update

RNS Number : 5752J

Shield Therapeutics PLC

31 December 2020

 

Shield Therapeutics plc

("Shield" or the "Group")

Total Voting Rights Update

London, UK, 31 December 2020:  Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ^® (ferric maltol), confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 117,620,190 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.

The above figure may also be used by shareholders as the denominator in the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Tim Watts, Chief Executive Officer	[phone]
Lucy Huntington-Bailey, General Counsel and Company Secretary	[phone]
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden	[phone]
Joint Broker finnCap Ltd  Geoff Nash/Matt Radley/Alice Lane	[phone]
Financial PR & IR Advisor
Walbrook PR	[phone] or  [e-mail]
Paul McManus/Lianne Cawthorne	[phone] / [phone]

About Shield Therapeutics plc

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com . Follow Shield on Twitter @ShieldTx

 

END

 

 

TVRZLLFLBLLXFBB